Mid-term Business Plan

2008 - 2010


November 5, 2007

Towa Pharmaceutical Co., Ltd.

(stock ticker number : 4553)

Position of the Mid-term Business Plan Period 3 years FY2008 - FY2010 (April 2008 – March 2011) Assumptions During the next 3 years, • Japanese generic drug (GE) market will expand gradually. • It will take a little while for full-scale widespread use of GE. Main purport of o clarify the measures to be implemented the Plan: based on the assumptions (In case of major changes in the assumptions,

we will revise the Plan and respond flexibly.)



• Survival conditions?

"Quality, service, and price (cost) competitiveness of a global standard"


Corporate Vision




To be trusted by patients, medical professionals, society and employees


To be the leading GE company by reliability and sales volume, and to contribute to the future medication

As a result, to achieve 50 bn yen sales after 5 years (in 2012), and 100 bn yen sales in the future



Quality, information provision, stable supply at the level required from the market








Reinforcement of GP, small and mid-sized HP and pharmacy market, where Towa has an advantage

Fair pricing strategy


Organizing sales agents and branch networks

2. Reinforcement of GP, small and mid-sized HP and pharmacy market

Focusing on DPC prep-HPs and public HPs among HP market



(non-consolidated)




- 9 -

Target figures


(Yen in millions)

				/
	FY2007	FY2008	FY2009	FY2010
Net Sales	32,400	35,200	37,500	41,200
(change in %)	(+10.8%)	(+8.6%)	(+6.5%)	(+9.9%)
Gross Margin	15,370	17,000	18,600	20,600
(change in %)	(+12.6%)	(+10.6%)	(+9.4%)	(+10.8%)
Gross Margin Rate	47.4%	48.3%	49.6%	50.0%
SGA	9,770	11,000	11,700	12,100
(change in %)	(+5.9%)	(+12.6%)	(+6.4%)	(+3.4%)
Operating Income	5,600	6,000	6,900	8,500
(change in %)	(+26.8%)	(+7.1%)	(+15.0%)	(+23.2%)
Ordinary Income	5,800	6,200	7,100	8,700
Net Income	3,550	3,720	4,260	5,220


Target figures




R&D expenditure



Capital expenditure



Sales plan by launched year






J-DOLPH Pharmaceutical CO.,LTD.

Specialty

Specialized in information provision on hemorrhoidal preparations focusing on promotion to proctologists

Improvement of productivity in Towa group

Contract manufacturing of Towa products (liquid and ointment formulation)



- Balancing stable cash dividends and adequate earning retention
 - Yamagata Plant renewal
 - Funding for taking actions to business environmental changes

Contact information
Yoshifumi TOGO
Deputy General Manager
Management Planning Development
Corporate Planning Division
Towa Pharmaceutical Co., Ltd.
y-togo@towayakuhin.co.jp
TEL : +81-6-6900-9101
FAX : +81-6-6900-0634

Disclaimer

This presentation contains forward-looking statements related to management's expectations about future business conditions. Actual business conditions may differ significantly from management's expectation and accordingly affect the Company's sales and profitability. Actual results may differ because of factors over which the Company has no control, including unexpected changes in competitive and economic conditions, government regulations, technology and other factors